CD19 Antibody (HIB19): sc-19650

CD19 Antibody (HIB19) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD19 protein of human origin by immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD19 (HIB19) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD19 is a crucial transmembrane glycoprotein that plays a significant role in B-cell development and function, as CD19 is selectively expressed on the surface of B-lymphocytes. CD19 contains two extracellular immunoglobulin-like domains, which are essential for interaction with other surface proteins and for initiating intracellular signaling cascades. CD19 activation leads to the cross-linking of immunoglobulin chains and the recruitment of Src family protein tyrosine kinases, which are vital for the propagation of signals that promote B-cell activation and proliferation. CD19 forms functional complexes with other B-lymphocyte surface proteins, such as integrin β1, CD21, and CD81, which are integral to regulating B-cell development and ensuring a robust immune response. CD19 continuous expression throughout B-cell maturation and involvement in the terminal differentiation of B-cells into plasma cells underscore CD19′s importance in both adaptive immunity and potential therapeutic targeting in B-cell malignancies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD19 Antibody (HIB19) References:

1. Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes.  |  Zhou, LJ., et al. 1992. Immunogenetics. 35: 102-11. PMID: 1370948
2. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.  |  Carter, RH. and Fearon, DT. 1992. Science. 256: 105-7. PMID: 1373518
3. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules.  |  Bradbury, LE., et al. 1992. J Immunol. 149: 2841-50. PMID: 1383329
4. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation.  |  Pezzutto, A., et al. 1987. J Immunol. 138: 2793-9. PMID: 2437199
5. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.  |  Bregni, M., et al. 1989. Blood. 73: 753-62. PMID: 2465042
6. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily.  |  Tedder, TF. and Isaacs, CM. 1989. J Immunol. 143: 712-7. PMID: 2472450
7. Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation.  |  Mancusi, A., et al. 2023. Int J Mol Sci. 24: PMID: 38003295
8. CD19+CD73+ B cells infiltration indicates poor prognosis and unfavorable responses to immunotherapy in gastric cancer.  |  Zhang, Y., et al. 2024. Int Immunopharmacol. 141: 113002. PMID: 39213870
9. Recent developments in CD19-targeted therapies for follicular lymphoma.  |  Saha, A. and Chavez, JC. 2024. Expert Opin Biol Ther. 24: 1049-1055. PMID: 39291554
10. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development.  |  Zhou, LJ., et al. 1994. Mol Cell Biol. 14: 3884-94. PMID: 7515149
11. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors.  |  Weng, WK., et al. 1994. J Biol Chem. 269: 32514-21. PMID: 7528218
12. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny.  |  Uckun, FM., et al. 1993. J Biol Chem. 268: 21172-84. PMID: 7691807

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD19 Antibody (HIB19) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-CD19 Antibody (HIB19) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD19 Antibody (HIB19) Specifications

Alternate Product Name: CD19

Product Clone Name: HIB19

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CD19

Epitope Species: human

Product Reactivity/Detection: CD19

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: IF, IHC(P), FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for CD19 Antibody (HIB19): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin